Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

被引：1

作者：

Hernando, J. ^{[1
]}

Manzano, J. L. ^{[2
]}

Teule, A. ^{[3
]}

Lopez, C. ^{[4
]}

Garcia-Carbonero, R. ^{[5
]}

Benavent Vinuales, M. ^{[6
]}

Custodio, A. ^{[7
]}

Cubillo, A. ^{[8
]}

Alonso, V. ^{[9
]}

Alonso-Gordoa, T. ^{[10
]}

Carmona-Bayonas, A. ^{[11
]}

Crespo, G. ^{[12
]}

Blanco, M. ^{[13
]}

Jimenez-Fonseca, P. ^{[14
]}

Viudez, A. ^{[15
]}

La Casta, A. ^{[16
]}

Sevilla, I. ^{[17
]}

Llanos, M. ^{[18
]}

Segura, A. ^{[19
]}

Capdevila, J. ^{[1
]}

机构：

[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[2] Inst Catala Oncol ICO Badalona, Hosp Germans Trias i Pujol, Dept Med Oncol, Badalona, Spain

[3] Inst Catala Oncol ICO IDIBELL, Med Oncol Dept, Lhospitalet De Llobregat, Spain

[4] Hosp Univ Marques Valdecilla, IDIVAL, Med Oncol Dept, Santander, Spain

[5] Hosp Univ 12 Octubre, Imas12, UCM CNIO, Med Oncol Dept, Madrid, Spain

[6] Univ Hosp Virgen Rocio, Inst Biomed Sevilla IBIS, Med Oncol Dept, Seville, Spain

[7] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[8] Hosp Univ HM Sanchinarro, Med Oncol Dept, Madrid, Spain

[9] Inst Invest Sanitaria Aragon IISA, Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[10] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain

[11] Hosp Univ Morales Meseguer, UMU, IMIB, Hematol & Med Oncol Dept, Murcia, Spain

[12] Complejo Asistencial Univ Burgos, Med Oncol Dept, Burgos, Spain

[13] Hosp Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

[14] Hosp Univ Cent Asturias, ISPA, Med Oncol Dept, Oviedo, Spain

[15] Complejo Hosp Navarra, Medica Oncol Dept, Pamplona, Spain

[16] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain

[17] Hosp Univ Reg & Virgen Victoria Malaga, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Med Oncol Dept, Malaga, Spain

[18] Hosp Univ Canarias, Med Oncol Dept, San Cristobal la Laguna, Spain

[19] Hosp Univ Fe, Med Oncol Dept, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1099MO

引用

页码：S909 / S910

页数：2

共 31 条

[1] Final results from the DUNE trial (GETNE 1601): Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins
Capdevila, J.
Teule, A.
Hernando, J.
Lopez, C.
Garcia-Carbonero, R.
Vinuales, Benavent
Custodio, A.
Cubillo, A.
Alonso, V
Landolfi, S.
Alvarez A, Garcia
Manzano, J. L.
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 170 - 170
[2] Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)
Hernando-Cubero, J.
Manzano, J. L.
Benavent, M.
Lopez, C.
Teule, R.
Garcia-Carbonero, R.
Carmona-Bayonas, A.
Crespo, G.
Cubillo, A.
Jimenez-Fonseca, P.
LaCasta, A.
Capdevila, J.
NEUROENDOCRINOLOGY, 2018, 106 : 228 - 228
[3] A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).
Garcia, Ignacio Matos
Grande, Enrique
Garcia-Carbonero, Rocio
Lopez, Carlos
Teule, Alexandre
Capdevila, Jaume
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
Capdevila, J.
Landolfi, S.
Hernando, J.
Teule, A.
Garcia-Carbonero, R.
Custodio, A.
Cubillo, A.
Alonso-Gordoa, T.
Carmona-Bayonas, A.
Crespo, G.
Blanco, M.
Viudez, A.
La Casta, A.
Sevilla, I.
Segura, A.
Lopez, C.
Benavent Vinuales, M.
Nuciforo, P.
Manzano, J. L.
ANNALS OF ONCOLOGY, 2021, 32 : S914 - S915
[5] A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Capdevila, J.
Teule, A.
Lopez, C.
Garcia-Carbonero, R.
Benavent, M.
Custodio, A.
Cubillo, A.
Alonso, V.
Alonso Gordoa, T.
Carmona-Bayonas, A.
Crespo, G.
Blanco-Codesido, M.
Jimenez-Fonseca, P.
Viudez, A.
La Casta Munoa, A.
Sevilla, I.
Llanos, M.
Segura, A.
Hernando-Cubero, J.
Manzano, J. L.
ANNALS OF ONCOLOGY, 2020, 31 : S770 - S771
[6] Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).
Hernando, Jorge
Molina-Cerrillo, Javier
Grande, Enrique
Benavent Vinuales, Marta
Garcia-Carbonero, Rocio
Teule, Alex
Custodio, Ana
Jimenez-Fonseca, Paula
Hierro, Cinta
Lopez Lopez, Carlos
Sevilla, Isabel
Llanos, Marta
Carmona-Bayonas, Alberto
Alonso, Vicente
Gallego, Javier
Gallego Jimenez, Inmaculada
Orta, Alberto
Franco, Fernando
Garcia-Alvarez, Alejandro
Capdevila, Jaume
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)
Hernando Cubero, J.
Taberna Sanz, M.
Carmona Bayonas, A.
Iglesias, L.
Grande, E.
Trigo Perez, J. M.
Grau, J. J.
Lopez-Picazo, J. M.
Castelo, B.
Alonso Gordoa, T.
Lorenzo, I.
Casado Herraez, A.
Ugidos, L.
Munarriz, J.
Lavernia, J.
Capdevila, J.
ANNALS OF ONCOLOGY, 2019, 30 : 759 - 759
[8] Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)
Molina-Cerrillo, J.
Grande, E.
Benavent, M.
Garcia-Carbonero, R.
Teule, A.
Custodio, A.
Jimenez-Fonseca, P.
Hierro, C.
Lopez, C.
Sevilla, I
Llanos, M.
Capdevila, J.
JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 245 - 245
[9] Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
Riesco-Martinez, M. C.
Capdevila, J.
Alonso, V.
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I.
Benavent Vinuales, M.
Alonso-Gordoa, T.
Custodio, A.
Hernando, J.
Polo, E.
Castillo Trujillo, O. A.
Garcia-Carbonero, R.
ANNALS OF ONCOLOGY, 2021, 32 : S908 - S909
[10] Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
Riesco Martinez, M. C.
Capdevila Castillon, J.
Alonso, V.
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I.
Benavent, M.
Alonso-Gordoa, T.
Custodio, A.
Anton Pascual, B.
Hernando, J.
Polo, E.
Castillo Trujillo, O. A.
Garcia-Carbonero, R.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S769 - S769

← 1 2 3 4 →